Business Context and Reporting Period
Company: Icecure Medical Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: January 2025 (Report dated January 27, 2025)
Principal Executive Office: Caesarea, Israel
This filing reports the issuance of a press release on January 27, 2025, announcing that the Company has filed for regulatory approval of its ProSense® Cryoablation System in China.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 6-K serves solely to disclose a corporate event and incorporates a press release by reference; it does not contain financial statements or quantitative performance data.
Material Changes
Regulatory Milestone: The Company has submitted an application for regulatory approval of the ProSense® Cryoablation System in the Chinese market. This represents a strategic expansion effort into a key international market.
Guidance, Outlook, and Risks
Outlook: The filing indicates progress in the Company's commercialization strategy by seeking approval in China. The press release incorporated by reference contains a section titled "Forward Looking Statements," though the specific content of those statements is not detailed in the Form 6-K text provided.
Risks and Contingencies: The filing does not explicitly list risks or contingencies within the body text, other than the inherent uncertainty associated with pending regulatory approvals.
Investor Verification Checklist
- Verify the specific regulatory body in China receiving the ProSense® Cryoablation System application.
- Review the full text of the press release (Exhibit 99.1) for detailed "Forward Looking Statements" and risk factors.
- Monitor future filings for updates on the status of the Chinese regulatory approval process.
- Check subsequent financial reports (e.g., Form 20-F) for the financial impact of this expansion initiative.